BioDelivery Scis. Int’l v. Aquestive Therapeutics, Inc. (Fed. Cir .2019) The determination by the Director whether to institute an inter partes review under this section shall be final and nonappealable. 35 U.S.C. 314(d). In 2014, BioDelivery filed three separate IPR petitions against Aquestive’s U.S. Patent 8,765,167.  The USPTO partially-instituted the proceedings (on some, but not all grounds) … Continue reading Final and Nonappealable: construed as “may be reconsidered” and not reviewable in “at least some circumstances.”